Fredrik Svensson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fredrik Svensson has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Bender
Department of Medicine and Center for Biotechnology, College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates
10 shared publications - Ulf Norinder
Örebro University
9 shared publications - Christian Sköld
Uppsala University
6 shared publications Magda Bictash
Alzheimer’s Research UK UCL Drug Discovery Institute, University College London, Cruciform Building, Gower Street, London WC1E 6BT, U.K.
6 shared publications- Paul V. Fish
Alzheimer's Research UK UCL Drug Discovery Institute, University College London, Cruciform Building, Gower Street, London, WC1E 6BT, UK
6 shared publications Sarah Frew
Alzheimer's Research UK UCL Drug Discovery Institute, University College London, The Cruciform Building, Gower Street, London, WC1E 6BT, UK
6 shared publications
Latest Publications
- Open Access
- 29 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Design and synthesis of a chemically diverse, lead-like DNA-encoded library from sequential amide coupling
Accessible synthesis of DNA-encoded libraries of up to 3 million-members via sequential amide coupling, validated by CAIX screening. In silico analysis showed lead-like properties, and the libraries are available to support academic drug discovery.
- 29 July 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
Open AccessDesign and synthesis of a chemically diverse, lead-like DNA-encoded library from sequential amide coupling
Accessible synthesis of DNA-encoded libraries of up to 3 million-members via sequential amide coupling, validated by CAIX screening. In silico analysis showed lead-like properties, and the libraries are available to support academic drug discovery.
- 20 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 10507-10519
Computational Hit Finding: An Industry Perspective
Computational hit finding, particularly virtual screening, has been a mainstay of drug discovery campaigns for decades, providing a cost-efficient complement to wet experiments. Innovation in this space slowed considerably as these approaches converged around mature software programs and stock chemical libraries up to ∼10 million in size. Recently, however, powered by massive increases in computational power, the emergence of ultralarge make-on-demand virtual libraries, the development of large capacity neural networks, the expansion of the domain of applicability of free energy calculations, and advances in protein structure prediction, the virtual screening field is currently seeing major change. We present a guide from industry practitioners summarizing key aspects on the changing computational hit finding landscape including practical recommendations for building a performant end-to-end screening workflow, strategies to mitigate risk by avoiding common pitfalls, determining success criteria, and a brief discussion of emerging technologies likely to impact drug discovery in the near future.
- 20 May 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (11) , 10507-10519
Computational Hit Finding: An Industry Perspective
Computational hit finding, particularly virtual screening, has been a mainstay of drug discovery campaigns for decades, providing a cost-efficient complement to wet experiments. Innovation in this space slowed considerably as these approaches converged around mature software programs and stock chemical libraries up to ∼10 million in size. Recently, however, powered by massive increases in computational power, the emergence of ultralarge make-on-demand virtual libraries, the development of large capacity neural networks, the expansion of the domain of applicability of free energy calculations, and advances in protein structure prediction, the virtual screening field is currently seeing major change. We present a guide from industry practitioners summarizing key aspects on the changing computational hit finding landscape including practical recommendations for building a performant end-to-end screening workflow, strategies to mitigate risk by avoiding common pitfalls, determining success criteria, and a brief discussion of emerging technologies likely to impact drug discovery in the near future.
- Open Access
- 21 January 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 251, 115132
Designed switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity
- 21 January 2023
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 251, 115132
Open AccessDesigned switch from covalent to non-covalent inhibitors of carboxylesterase Notum activity
- Open Access
- 10 May 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (10) , 7212-7230
Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit
Notum is a carboxylesterase that suppresses Wnt signaling through deacylation of an essential palmitoleate group on Wnt proteins. There is a growing understanding of the role Notum plays in human diseases such as colorectal cancer and Alzheimer's disease, supporting the need to discover improved inhibitors, especially for use in models of neurodegeneration. Here, we have described the discovery and profile of 8l (ARUK3001185) as a potent, selective, and brain-penetrant inhibitor of Notum activity suitable for oral dosing in rodent models of disease. Crystallographic fragment screening of the Diamond-SGC Poised Library for binding to Notum, supported by a biochemical enzyme assay to rank inhibition activity, identified 6a and 6b as a pair of outstanding hits. Fragment development of 6 delivered 8l that restored Wnt signaling in the presence of Notum in a cell-based reporter assay. Assessment in pharmacology screens showed 8l to be selective against serine hydrolases, kinases, and drug targets.
- 10 May 2022
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (10) , 7212-7230
Open AccessDesign of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit
Notum is a carboxylesterase that suppresses Wnt signaling through deacylation of an essential palmitoleate group on Wnt proteins. There is a growing understanding of the role Notum plays in human diseases such as colorectal cancer and Alzheimer's disease, supporting the need to discover improved inhibitors, especially for use in models of neurodegeneration. Here, we have described the discovery and profile of 8l (ARUK3001185) as a potent, selective, and brain-penetrant inhibitor of Notum activity suitable for oral dosing in rodent models of disease. Crystallographic fragment screening of the Diamond-SGC Poised Library for binding to Notum, supported by a biochemical enzyme assay to rank inhibition activity, identified 6a and 6b as a pair of outstanding hits. Fragment development of 6 delivered 8l that restored Wnt signaling in the presence of Notum in a cell-based reporter assay. Assessment in pharmacology screens showed 8l to be selective against serine hydrolases, kinases, and drug targets.
- Open Access
- 23 February 2022
- Published by Royal Society of Chemistry (RSC) in Digital Discovery
- Vol. 1 (2) , 158-172
Consideration of predicted small-molecule metabolites in computational toxicology
Xenobiotic metabolism has evolved as a key protective system of organisms against potentially harmful chemicals or compounds typically not present in a particular organism. The system's primary purpose is to chemically transform xenobiotics into metabolites that can be excreted via renal or biliary routes. However, in a minority of cases, the metabolites formed are toxic, sometimes even more toxic than the parent compound. Therefore, the consideration of xenobiotic metabolism clearly is of importance to the understanding of the toxicity of a compound. Nevertheless, most of the existing computational approaches for toxicity prediction do not explicitly take metabolism into account and it is currently not known to what extent the consideration of (predicted) metabolites could lead to an improvement of toxicity prediction. In order to study how predictive metabolism could help to enhance toxicity prediction, we explored a number of different strategies to integrate predictions from a state-of-the-art metabolite structure predictor and from modern machine learning approaches for toxicity prediction. We tested the integrated models on five toxicological endpoints and assays, including in vitro and in vivo genotoxicity assays (AMES and MNT), two organ toxicity endpoints (DILI and DICC) and a skin sensitization assay (LLNA). Overall, the improvements in model performance achieved by including metabolism data were minor (up to +0.04 in the F1 scores and up to +0.06 in MCCs). In general, the best performance was obtained by averaging the probability of toxicity predicted for the parent compound and the maximum probability of toxicity predicted for any metabolite. Moreover, including metabolite structures as further input molecules for model training slightly improved the toxicity predictions obtained by this averaging approach. However, the high complexity of the metabolic system and associated uncertainty about the likely metabolites apparently limits the benefit of considering predicted metabolites in toxicity prediction.
- 23 February 2022
- Published by Royal Society of Chemistry (RSC) in Digital Discovery
- Vol. 1 (2) , 158-172
Open AccessConsideration of predicted small-molecule metabolites in computational toxicology
Xenobiotic metabolism has evolved as a key protective system of organisms against potentially harmful chemicals or compounds typically not present in a particular organism. The system's primary purpose is to chemically transform xenobiotics into metabolites that can be excreted via renal or biliary routes. However, in a minority of cases, the metabolites formed are toxic, sometimes even more toxic than the parent compound. Therefore, the consideration of xenobiotic metabolism clearly is of importance to the understanding of the toxicity of a compound. Nevertheless, most of the existing computational approaches for toxicity prediction do not explicitly take metabolism into account and it is currently not known to what extent the consideration of (predicted) metabolites could lead to an improvement of toxicity prediction. In order to study how predictive metabolism could help to enhance toxicity prediction, we explored a number of different strategies to integrate predictions from a state-of-the-art metabolite structure predictor and from modern machine learning approaches for toxicity prediction. We tested the integrated models on five toxicological endpoints and assays, including in vitro and in vivo genotoxicity assays (AMES and MNT), two organ toxicity endpoints (DILI and DICC) and a skin sensitization assay (LLNA). Overall, the improvements in model performance achieved by including metabolism data were minor (up to +0.04 in the F1 scores and up to +0.06 in MCCs). In general, the best performance was obtained by averaging the probability of toxicity predicted for the parent compound and the maximum probability of toxicity predicted for any metabolite. Moreover, including metabolite structures as further input molecules for model training slightly improved the toxicity predictions obtained by this averaging approach. However, the high complexity of the metabolic system and associated uncertainty about the likely metabolites apparently limits the benefit of considering predicted metabolites in toxicity prediction.
- 23 December 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (1) , 562-578
Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity
Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Inhibitors of Notum could be of use in diseases where dysfunctional Notum activity is an underlying cause. A docking-based virtual screen (VS) of a large commercial library was used to shortlist 952 compounds for experimental validation as inhibitors of Notum. The VS was successful with 31 compounds having an IC50 < 500 nM. A critical selection process was then applied with two clusters and two singletons (1–4d) selected for hit validation. Optimization of 4d guided by structural biology identified potent inhibitors of Notum activity that restored Wnt/β-catenin signaling in cell-based models. The [1,2,4]triazolo[4,3-b]pyradizin-3(2H)-one series 4 represent a new chemical class of Notum inhibitors and the first to be discovered by a VS campaign. These results demonstrate the value of VS with well-designed docking models based on X-ray structures.
- 23 December 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (1) , 562-578
Virtual Screening Directly Identifies New Fragment-Sized Inhibitors of Carboxylesterase Notum with Nanomolar Activity
Notum is a negative regulator of Wnt signaling acting through the hydrolysis of a palmitoleoylate ester, which is required for Wnt activity. Inhibitors of Notum could be of use in diseases where dysfunctional Notum activity is an underlying cause. A docking-based virtual screen (VS) of a large commercial library was used to shortlist 952 compounds for experimental validation as inhibitors of Notum. The VS was successful with 31 compounds having an IC50 < 500 nM. A critical selection process was then applied with two clusters and two singletons (1–4d) selected for hit validation. Optimization of 4d guided by structural biology identified potent inhibitors of Notum activity that restored Wnt/β-catenin signaling in cell-based models. The [1,2,4]triazolo[4,3-b]pyradizin-3(2H)-one series 4 represent a new chemical class of Notum inhibitors and the first to be discovered by a VS campaign. These results demonstrate the value of VS with well-designed docking models based on X-ray structures.
- Open Access
- 2 October 2021
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 13 (1) , 1-11
Synergy conformal prediction applied to large-scale bioactivity datasets and in federated learning
Confidence predictors can deliver predictions with the associated confidence required for decision making and can play an important role in drug discovery and toxicity predictions. In this work we investigate a recently introduced version of conformal prediction, synergy conformal prediction, focusing on the predictive performance when applied to bioactivity data. We compare the performance to other variants of conformal predictors for multiple partitioned datasets and demonstrate the utility of synergy conformal predictors for federated learning where data cannot be pooled in one location. Our results show that synergy conformal predictors based on training data randomly sampled with replacement can compete with other conformal setups, while using completely separate training sets often results in worse performance. However, in a federated setup where no method has access to all the data, synergy conformal prediction is shown to give promising results. Based on our study, we conclude that synergy conformal predictors are a valuable addition to the conformal prediction toolbox.
- 2 October 2021
- Published by Springer Nature in Journal of Cheminformatics
- Vol. 13 (1) , 1-11
Open AccessSynergy conformal prediction applied to large-scale bioactivity datasets and in federated learning
Confidence predictors can deliver predictions with the associated confidence required for decision making and can play an important role in drug discovery and toxicity predictions. In this work we investigate a recently introduced version of conformal prediction, synergy conformal prediction, focusing on the predictive performance when applied to bioactivity data. We compare the performance to other variants of conformal predictors for multiple partitioned datasets and demonstrate the utility of synergy conformal predictors for federated learning where data cannot be pooled in one location. Our results show that synergy conformal predictors based on training data randomly sampled with replacement can compete with other conformal setups, while using completely separate training sets often results in worse performance. However, in a federated setup where no method has access to all the data, synergy conformal prediction is shown to give promising results. Based on our study, we conclude that synergy conformal predictors are a valuable addition to the conformal prediction toolbox.
- Open Access
- 22 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (15) , 11354-11363
Structural Insights into Notum Covalent Inhibition
The carboxylesterase Notum hydrolyzes a palmitoleate moiety from Wingless/Integrated(Wnt) ligands and deactivates Wnt signaling. Notum inhibitors can restore Wnt signaling which may be of therapeutic benefit for pathologies such as osteoporosis and Alzheimer’s disease. We report the identification of a novel class of covalent Notum inhibitors, 4-(indolin-1-yl)-4-oxobutanoate esters. High-resolution crystal structures of the Notum inhibitor complexes reveal a common covalent adduct formed between the nucleophile serine-232 and hydrolyzed butyric esters. The covalent interaction in solution was confirmed by mass spectrometry analysis. Inhibitory potencies vary depending on the warheads used. Mechanistically, the resulting acyl-enzyme intermediate carbonyl atom is positioned at an unfavorable angle for the approach of the active site water, which, combined with strong hydrophobic interactions with the enzyme pocket residues, hinders the intermediate from being further processed and results in covalent inhibition. These insights into Notum catalytic inhibition may guide development of more potent Notum inhibitors.
- 22 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (15) , 11354-11363
Open AccessStructural Insights into Notum Covalent Inhibition
The carboxylesterase Notum hydrolyzes a palmitoleate moiety from Wingless/Integrated(Wnt) ligands and deactivates Wnt signaling. Notum inhibitors can restore Wnt signaling which may be of therapeutic benefit for pathologies such as osteoporosis and Alzheimer’s disease. We report the identification of a novel class of covalent Notum inhibitors, 4-(indolin-1-yl)-4-oxobutanoate esters. High-resolution crystal structures of the Notum inhibitor complexes reveal a common covalent adduct formed between the nucleophile serine-232 and hydrolyzed butyric esters. The covalent interaction in solution was confirmed by mass spectrometry analysis. Inhibitory potencies vary depending on the warheads used. Mechanistically, the resulting acyl-enzyme intermediate carbonyl atom is positioned at an unfavorable angle for the approach of the active site water, which, combined with strong hydrophobic interactions with the enzyme pocket residues, hinders the intermediate from being further processed and results in covalent inhibition. These insights into Notum catalytic inhibition may guide development of more potent Notum inhibitors.
- 27 May 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 61 (6) , 2648-2657
Deep Learning-Based Conformal Prediction of Toxicity
Predictive modeling for toxicity can help reduce risks in a range of applications and potentially serve as the basis for regulatory decisions. However, the utility of these predictions can be limited if the associated uncertainty is not adequately quantified. With recent studies showing great promise for deep learning-based models also for toxicity predictions, we investigate the combination of deep learning-based predictors with the conformal prediction framework to generate highly predictive models with well-defined uncertainties. We use a range of deep feedforward neural networks and graph neural networks in a conformal prediction setting and evaluate their performance on data from the Tox21 challenge. We also compare the results from the conformal predictors to those of the underlying machine learning models. The results indicate that highly predictive models can be obtained that result in very efficient conformal predictors even at high confidence levels. Taken together, our results highlight the utility of conformal predictors as a convenient way to deliver toxicity predictions with confidence, adding both statistical guarantees on the model performance as well as better predictions of the minority class compared to the underlying models.
- 27 May 2021
- Published by American Chemical Society (ACS) in Journal of Chemical Information and Modeling
- Vol. 61 (6) , 2648-2657
Deep Learning-Based Conformal Prediction of Toxicity
Predictive modeling for toxicity can help reduce risks in a range of applications and potentially serve as the basis for regulatory decisions. However, the utility of these predictions can be limited if the associated uncertainty is not adequately quantified. With recent studies showing great promise for deep learning-based models also for toxicity predictions, we investigate the combination of deep learning-based predictors with the conformal prediction framework to generate highly predictive models with well-defined uncertainties. We use a range of deep feedforward neural networks and graph neural networks in a conformal prediction setting and evaluate their performance on data from the Tox21 challenge. We also compare the results from the conformal predictors to those of the underlying machine learning models. The results indicate that highly predictive models can be obtained that result in very efficient conformal predictors even at high confidence levels. Taken together, our results highlight the utility of conformal predictors as a convenient way to deliver toxicity predictions with confidence, adding both statistical guarantees on the model performance as well as better predictions of the minority class compared to the underlying models.
- Open Access
- 6 April 2021
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 16 (1) , 1-16
TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation
The central role of the resident innate immune cells of the brain (microglia) in neurodegeneration has become clear over the past few years largely through genome-wide association studies (GWAS), and has rapidly become an active area of research. However, a mechanistic understanding (gene to function) has lagged behind. That is now beginning to change, as exemplified by a number of recent exciting and important reports that provide insight into the function of two key gene products – TREM2 (Triggering Receptor Expressed On Myeloid Cells 2) and PLCγ2 (Phospholipase C gamma2) – in microglia, and their role in neurodegenerative disorders. In this review we explore and discuss these recent advances and the opportunities that they may provide for the development of new therapies.
- 6 April 2021
- Published by Springer Nature in Molecular Neurodegeneration
- Vol. 16 (1) , 1-16
Open AccessTREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation
The central role of the resident innate immune cells of the brain (microglia) in neurodegeneration has become clear over the past few years largely through genome-wide association studies (GWAS), and has rapidly become an active area of research. However, a mechanistic understanding (gene to function) has lagged behind. That is now beginning to change, as exemplified by a number of recent exciting and important reports that provide insight into the function of two key gene products – TREM2 (Triggering Receptor Expressed On Myeloid Cells 2) and PLCγ2 (Phospholipase C gamma2) – in microglia, and their role in neurodegenerative disorders. In this review we explore and discuss these recent advances and the opportunities that they may provide for the development of new therapies.